TY - JOUR T1 - Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia JF - Journal of Neurology, Neurosurgery & Psychiatry JO - J Neurol Neurosurg Psychiatry SP - 997 LP - 1004 DO - 10.1136/jnnp-2018-319784 VL - 90 IS - 9 AU - Lieke H H Meeter AU - Rebecca M E Steketee AU - Dina Salkovic AU - Maartje E Vos AU - Murray Grossman AU - Corey T McMillan AU - David J Irwin AU - Adam L Boxer AU - Julio C Rojas AU - Nicholas T Olney AU - Anna Karydas AU - Bruce L Miller AU - Yolande A L Pijnenburg AU - Frederik Barkhof AU - Raquel Sánchez-Valle AU - Albert Lladó AU - Sergi Borrego-Ecija AU - Janine Diehl-Schmid AU - Timo Grimmer AU - Oliver Goldhardt AU - Alexander F Santillo AU - Oskar Hansson AU - Susanne Vestberg AU - Barbara Borroni AU - Alessandro Padovani AU - Daniela Galimberti AU - Elio Scarpini AU - Jonathan D Rohrer AU - Ione O C Woollacott AU - Matthis Synofzik AU - Carlo Wilke AU - Alexandre de Mendonca AU - Rik Vandenberghe AU - Luisa Benussi AU - Roberta Ghidoni AU - Giuliano Binetti AU - Wiro J Niessen AU - Janne M Papma AU - Harro Seelaar AU - Lize C Jiskoot AU - Frank Jan de Jong AU - Laura Donker Kaat AU - Marta Del Campo AU - Charlotte E Teunissen AU - Esther E Bron AU - Esther Van den Berg AU - John C Van Swieten Y1 - 2019/09/01 UR - http://jnnp.bmj.com/content/90/9/997.abstract N2 - Background Semantic dementia (SD) is a neurodegenerative disorder characterised by progressive language problems falling within the clinicopathological spectrum of frontotemporal lobar degeneration (FTLD). The development of disease-modifying agents may be facilitated by the relative clinical and pathological homogeneity of SD, but we need robust monitoring biomarkers to measure their efficacy. In different FTLD subtypes, neurofilament light chain (NfL) is a promising marker, therefore we investigated the utility of cerebrospinal fluid (CSF) NfL in SD.Methods This large retrospective multicentre study compared cross-sectional CSF NfL levels of 162 patients with SD with 65 controls. CSF NfL levels of patients were correlated with clinical parameters (including survival), neuropsychological test scores and regional grey matter atrophy (including longitudinal data in a subset).Results CSF NfL levels were significantly higher in patients with SD (median: 2326 pg/mL, IQR: 1628–3593) than in controls (577 (446–766), p<0.001). Higher CSF NfL levels were moderately associated with naming impairment as measured by the Boston Naming Test (rs =−0.32, p=0.002) and with smaller grey matter volume of the parahippocampal gyri (rs =−0.31, p=0.004). However, cross-sectional CSF NfL levels were not associated with progression of grey matter atrophy and did not predict survival.Conclusion CSF NfL is a promising biomarker in the diagnostic process of SD, although it has limited cross-sectional monitoring or prognostic abilities. ER -